Hematopoietic anomalies fuels multiple sclerosis

References

[1] AbsintaM, MaricD, GharagozlooM, et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. Nature 2021;597:709–14.

[2] YongHYF, YongVW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol 2022;18:40–55.

[3] CreeBAC, Oksenberg JR, HauserSL. Multiple sclerosis: two decades of progress. Lancet Neurol 2022;21:211–4.

[4] RederAT, GencK, ByskoshPV, et al. Monocyte activation in multiple sclerosis. Mult Scler 1998;4:162–8.

[5] RumbleJM, HuberAK, KrishnamoorthyG, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med 2015;212: 23–35.

[6] ShiK, LiH, ChangT, et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell 2022;185:1–14.

[7] SugiyamaT, KoharaH, NodaM, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25:977–88.

[8] MillerAE, Chitnis T, CohenBA, et al; National Medical Advisory Committee of the National Multiple Sclerosis Society. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society. JAMA neurology 2021;78:241–6.

[9] NicholasRS, RhoneEE, MariottiniA, et al. Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series. Neurology 2021;97:e890–901.

[10] CugurraA, Mamuladze T, RustenhovenJ, et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 2021;373:eabf7844.

RIGHTS & PERMISSIONS

2022 The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.